CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 26, 2012--
Verastem, Inc., a biopharmaceutical company focused on discovering and
developing drugs to treat breast and other cancers by targeting cancer
stem cells, today announced the pricing of its initial public offering
of 5,500,000 shares of its common stock at $10.00 per share, before
underwriting discounts and commissions. All of the shares in the
offering are being sold by Verastem. The underwriters also have an
option for a period of 30 days to purchase up to an additional 825,000
shares of common stock from Verastem to cover over-allotments, if any.
The shares are expected to begin trading on the NASDAQ Global Market on
January 27, 2012 under the symbol "VSTM.”
UBS Investment Bank and Leerink Swann LLC are acting as joint
book-running managers for the offering. Lazard Capital Markets LLC,
Oppenheimer & Co. Inc. and Rodman & Renshaw, LLC are acting as
co-managers for the offering.
A registration statement relating to these securities was declared
effective by the Securities and Exchange Commission on January 26, 2012.
Copies of the final prospectus relating to this offering may be obtained
by contacting UBS Investment Bank, Attention: Prospectus Department, 299
Park Avenue, New York, NY 10171, (888) 827-7275, or Leerink Swann LLC,
Attention: Syndicate Department, One Federal Street, 37th Floor, Boston,
MA 02110, (800) 808-7525, ext. 4814.
Source: Verastem, Inc.
For Verastem, Inc.
Lacy Roosevelt, 617-520-7052
lroosevelt@webershandwick.com
View printer-friendly version
